ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.

Cancer Sci · 2025 · PMC12400061 · PMID 40618725

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

RNA sequencing (RNA‐Seq) analysis of the gene signature ratio of M1 and M2 macrophages showed a trend toward a dominant M1 macrophage phenotype in the gastric cancer tissues induced by ONO‐4578 and nivolumab treatment.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.